Atara Biotherapeutics, Inc.
ATRA
$7.32
-$0.28-3.68%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 128.94M | 100.44M | 62.39M | 34.70M | 8.57M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 128.94M | 100.44M | 62.39M | 34.70M | 8.57M |
| Cost of Revenue | 168.74M | 180.37M | 188.34M | 209.78M | 228.05M |
| Gross Profit | -39.80M | -79.93M | -125.96M | -175.07M | -219.48M |
| SG&A Expenses | 38.53M | 39.48M | 41.30M | 45.73M | 49.80M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 207.27M | 219.84M | 229.65M | 255.50M | 277.85M |
| Operating Income | -78.33M | -119.41M | -167.26M | -220.80M | -269.28M |
| Income Before Tax | -85.42M | -133.14M | -181.03M | -233.09M | -276.11M |
| Income Tax Expenses | -12.00K | 18.00K | 16.00K | 17.00K | 15.00K |
| Earnings from Continuing Operations | -85.40 | -133.16 | -181.05 | -233.11 | -276.13 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -85.40M | -133.16M | -181.05M | -233.11M | -276.13M |
| EBIT | -78.33M | -119.41M | -167.26M | -220.80M | -269.28M |
| EBITDA | -73.28M | -114.25M | -162.13M | -215.79M | -264.45M |
| EPS Basic | -12.87 | -25.66 | -39.12 | -52.94 | -65.27 |
| Normalized Basic EPS | -7.48 | -14.50 | -22.92 | -31.59 | -39.82 |
| EPS Diluted | -12.87 | -25.66 | -39.12 | -52.94 | -65.27 |
| Normalized Diluted EPS | -7.48 | -14.50 | -22.92 | -31.59 | -39.82 |
| Average Basic Shares Outstanding | 29.94M | 23.56M | 20.35M | 18.41M | 16.94M |
| Average Diluted Shares Outstanding | 29.94M | 23.56M | 20.35M | 18.41M | 16.94M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |